Products
Xencor is advancing into the clinic several proprietary XmAb® antibodies and XPro™ protein therapeutics against biologically validated targets for the treatment of cancer, autoimmune disease and inflammation. We manage the risk inherent in the development of drugs by addressing primarily biologically validated targets and by applying the unique capability of our PDA® technology platform to design protein therapeutics with novel molecular compositions and superior properties. The creation of a broad product portfolio increases opportunities for success.